2011
Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers
Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers. Journal Of The National Cancer Institute 2011, 103: 1871-1883. PMID: 22034635, PMCID: PMC3243675, DOI: 10.1093/jnci/djr438.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overBiopsyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCarcinoma, Squamous CellCryopreservationFemaleFreeze DryingGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMastectomyMicroarray AnalysisMiddle AgedRNA, NeoplasmSpecimen HandlingTime FactorsMelanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation
Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. European Journal Of Cancer 2011, 48: 12-23. PMID: 21741824, DOI: 10.1016/j.ejca.2011.06.025.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAlgorithmsBreast NeoplasmsCancer VaccinesCarcinomaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHealth Status IndicatorsHumansImmunotherapyMelanoma-Specific AntigensMicroarray AnalysisMiddle AgedReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsTriple-negative breast cancerCancer/testis antigensNegative breast cancerBreast cancerTestis antigensMelanoma antigen family AHuman epidermal growth factor receptor 2 (HER2) receptorsImmune response augmentationImmune-stimulatory drugsMAGE-A antigensHigh expressionLymph node statusDistinct disease subsetsLess prognostic valueHigher MAGELow MAGEWorse survivalNode statusPoor prognosisPrognostic valueDisease subsetsImmune infiltrationPredictive markerImmune metagenesImmune response
2009
Gene expression profiling of breast cancer
Pusztai L. Gene expression profiling of breast cancer. Breast Cancer Research 2009, 11: s11. PMID: 20030862, PMCID: PMC2797691, DOI: 10.1186/bcr2430.Peer-Reviewed Original Research
2006
Chips to Bedside: Incorporation of Microarray Data into Clinical Practice
Pusztai L. Chips to Bedside: Incorporation of Microarray Data into Clinical Practice. Clinical Cancer Research 2006, 12: 7209-7214. PMID: 17189391, DOI: 10.1158/1078-0432.ccr-06-2649.Peer-Reviewed Original ResearchPharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal Of Clinical Oncology 2006, 24: 4236-4244. PMID: 16896004, DOI: 10.1200/jco.2006.05.6861.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDoxorubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroarray AnalysisMiddle AgedNeoplasm StagingOligonucleotidesPaclitaxelPredictive Value of TestsReproducibility of ResultsROC CurveSensitivity and Specificity